- Home
- BKE vs IMNM Comparison
BKE vs IMNM Comparison
Compare BKE & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKE | IMNM |
|---|---|---|
| Founded | 1948 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BKE | IMNM |
|---|---|---|
| Price | $43.24 | $19.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $53.00 | $32.80 |
| AVG Volume (30 Days) | 492.9K | ★ 1.4M |
| Earning Date | 05-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | 6.43 | ★ 51.40 |
| EPS | ★ 0.92 | N/A |
| Revenue | ★ $1,297,835,000.00 | $6,941,000.00 |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $4.99 | $1,127.34 |
| P/E Ratio | $46.30 | ★ N/A |
| Revenue Growth | ★ 6.58 | N/A |
| 52 Week Low | $42.29 | $7.96 |
| 52 Week High | $61.69 | $27.65 |
Technical Indicators
Market Signals| Indicator | BKE | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 33.25 | 49.57 |
| Support Level | N/A | $19.28 |
| Resistance Level | $56.21 | $23.00 |
| Average True Range (ATR) | 1.25 | 0.83 |
| MACD | 0.08 | 0.24 |
| Stochastic Oscillator | 16.43 | 58.06 |
Price Performance
Historical ComparisonAbout BKE Buckle Inc. (The)
Buckle Inc is a retailer of casual apparel, footwear, and accessories. The company retails medium to affordable priced casual apparel, footwear, and accessories for fashion-conscious young men and women. It retails under the brand names 'Buckle' and 'The Buckle'. Buckle markets a wide selection of mostly brand-name casual apparel including denim, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear.
About IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.